US Pat. No. 10,429,300

SURFACE PLASMON RESONANCE APPROACH TO MONITOR PROTEIN-LIGAND INTERACTIONS

The Johns Hopkins Univers...

1. A method of identifying a ligand that binds to a paddle motif peptide, the method comprising:a) contacting a paddle motif peptide immobilized on a sensor chip with a test molecule, wherein the paddle motif peptide comprises SEQ ID NO: 2 or SEQ ID NO: 4;
b) detecting binding of the ligand and the paddle motif peptide using surface plasmon resonance (SPR), thereby identifying the test molecule as a ligand that binds the paddle motif peptide.
US Pat. No. 10,426,738

POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE

ModernaTX, Inc., Cambrid...

1. A messenger RNA (mRNA) comprisingan open reading frame (ORF) encoding the human methylmalonyl-CoA mutase (MCM) polypeptide of SEQ ID NO:213, wherein the ORF is at least 99% identical to the nucleotide sequence of SEQ ID NO:732.
US Pat. No. 10,427,251

FINE SILVER PARTICLE DISPERSION, FINE SILVER PARTICLES, AND METHOD FOR PRODUCING SAME

BANDO CHEMICAL INDUSTRIES...

1. A fine silver particle dispersion, which comprisesfine silver particles,
a short chain amine having 5 or less carbon atoms and
a highly polar solvent,
wherein a partition coefficient log P of the short chain amine is ?1.0 to 1.4 and
wherein the short amine is an alkoxyamine.
US Pat. No. 10,428,023

HETEROCYCLIC COMPOUND AND USE THEREOF

Takeda Pharmaceutical Com...

1. N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3?,5?-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide or a salt thereof.
US Pat. No. 10,428,279

ELECTROLYZED WATER-AMINE COMPOSITIONS AND METHODS OF USE

1. A method of killing sulphate reducing microorganisms or microorganisms which can generate hydrogen sulphide, comprising the step of contacting the microorganism with a treatment fluid comprising a reaction product of electrolyzed water and an amine.
US Pat. No. 10,429,306

SURFACE PLASMON RESONANCE FLUORESCENCE ANALYSIS DEVICE AND SURFACE PLASMON RESONANCE FLUORESCENCE ANALYSIS METHOD

KONICA MINOLTA, INC., To...

1. A surface plasmon resonance fluorescence analysis device to which an analysis chip including a prism having a metal film provided on one surface of the prism is attached, and in which the metal film is irradiated with excitation light through the prism to excite a fluorescence material for labelling a substance to be detected on the metal film and fluorescence emitted from the fluorescence material is detected to detect presence or an amount of the substance to be detected, the surface plasmon resonance fluorescence analysis device comprising:a chip holder configured to detachably hold the analysis chip;
a light source configured to emit excitation light;
an angle adjusting section configured to adjust an incident angle of the excitation light with respect to the metal film to irradiate the metal film with the excitation light through the prism at a predetermined incident angle;
a first light sensor configured to detect fluorescence emitted from the fluorescence material;
a light reception optical system configured to guide light emitted from the metal film to the first light sensor;
an excitation light reflection filter disposed in the light reception optical system, and configured to reflect light having a wavelength same as that of the excitation light emitted from the light source in the light emitted from the metal film;
a second light sensor configured to detect the light reflected by the excitation light reflection filter; and
a control section configured to control the angle adjusting section; wherein
the control section controls the incident angle of the excitation light with respect to the metal film to be adjusted by the angle adjusting section on a basis of a detection result of the light obtained by the second light sensor.
US Pat. No. 10,428,281

TRANSITION METAL TUNGSTEN OXY-HYDROXIDE

UOP LLC, Des Plaines, IL...

1. A conversion process comprising contacting a feed with a catalyst at conversion conditions to give at least one product, the catalyst comprising the decomposition product of the decomposition by sulfidation of a metal tungsten oxy-hydroxide material having the formula:Sa(NH4)bM(OH)xWyOz where ‘S’ is a sugar selected from glucose, fructose, galactose, lactose, maltose, sucrose, and mixtures thereof; ‘a’ varies from 0.001 to 5; ‘b’ varies from 0.1 and 3 ‘M’ is a metal selected from Mg, Mn, Fe, Co, Ni, Cu, Zn, and combinations thereof; ‘x’ varies from 0.1 to 2; ‘y’ varies from 0.1 to 4; z is a number which satisfies the sum of the valences of M, b, x and y; the material having a poorly crystalline diffraction pattern showing a broad peak between d-spacing 4.45-2.25 ?.
US Pat. No. 10,427,003

GOLF BALL HAVING AT LEAST ONE LAYER CONSISTING OF A MIXTURE OF A THERMOSET OR THERMOPLASTIC COMPOSITION AND A PLURALITY OF ALKOXYLATED SILOXANE-SURFACE TREATED PARTICLES AND/OR POLYETHER-MODIFIED SILOXANE-SURFACE TREATED PARTICLES

Acushnet Company, Fairha...

1. A golf ball having a CoR of at least 0.700 and an Atti compression of at least about 50 and comprising at least one layer comprising a mixture of a polyurethane composition and a plurality of titanium dioxide particulates, wherein at least a portion of the plurality is surface-treated with alkoxylated siloxanes, polyether-modified siloxanes, or combinations thereof;wherein the plurality of titanium dioxide particulates is included in the mixture in an amount such that the cover layer has a specific gravity of from 0.5 to about 5.0 and greater than a specific gravity of the polyurethane composition; and
wherein the plurality of titanium dioxide particulates creates a specific gravity gradient within the cover layer.
US Pat. No. 10,428,283

REACTOR WITH STRIPPING ZONE

UOP LLC, Des Plaines, IL...

1. A hydrotreating process comprising:providing a feed stream to a hydrotreating vessel, where the hydrotreating vessel comprises an upper zone, an intermediate zone and a lower zone;
passing the feed stream through the upper zone of the hydrotreating vessel, wherein the upper zone includes at least one upper catalyst bed;
separating a gas from a liquid within the intermediate zone;
passing the gas separated within the intermediate zone out of the hydrotreating vessel, said step of passing the separated gas comprises passing the separated gas through a heat exchanger and separating the vapor and liquid phase in a separator and routing liquid effluent from the separator back to said intermediate zone of the hydrotreating vessel;
providing a stripping gas to the lower zone through a first gas line;
replacing gas separated within the intermediate zone in the lower zone with a replacement gas via a second gas line in the lower zone; and
passing the liquid within the intermediate zone to the lower zone, wherein the lower zone includes a packed section wherein the liquid is contacted in counter current fashion with the stripping gas to remove impurities;
passing the liquid through to at least one lower catalyst in the lower zone,
wherein the step of removing impurities involves removing hydrogen sulfide and ammonia; and further wherein the hydrogen sulfide and the ammonia are passed out of the hydrotreating vessel during said step of passing the gas separated out of the hydrotreating vessel.
US Pat. No. 10,427,004

GOLF BALLS INCORPORATING THERMOPLASTIC BLENDS(S) OF IONOMER(S), THERMOPLASTIC POLYMER(S), PGM REACTIVE CROSSLINKER(S), AND CATALYST(S)

Acushnet Company, Fairha...

1. A golf ball comprising a core and at least one layer comprising a thermoplastic blend of (i) at least one ionomer; (ii) at least one thermoplastic polyurethane; (iii) at least one reactive crosslinker consisting of maleic group-modified polymer(s), glycidyl (meth)acrylate-modified polymer(s), or combinations thereof (“PGM”); and (iv) at least one catalyst;wherein the ionomer is present in an amount of about 45 wt % or greater and the PGM is present in an amount of from about 2 wt % to about 35 wt %.
US Pat. No. 10,427,006

GOLF BALL INCORPORATING AT LEAST ONE LAYER OF PLASTICIZED NEUTRALIZED ACID POLYMER COMPOSITION CONTAINING LOW MOLECULAR WEIGHT ACID WAX(ES) AS SOLE ACID POLYMER COMPONENT AND LOW MOLECULAR WEIGHT NON-ACID WAX(ES) IN THE NON-ACID POLYMER COMPONENT

Acushnet Company, Fairha...

1. A golf ball comprising at least one layer consisting of a plasticized neutralized acid polymer composition consisting of a mixture of: (a) at least one low molecular weight acid-containing wax; (b) at least one non-acid-polymer, of which at least one is a low molecular weight non-acid wax; (c) at least one organic acid or salt thereof; and (d) at least one plasticizer;wherein each low molecular weight acid-containing wax has a molecular weight of from about 500 to about 30,000;
wherein the mixture contains at least 70 percent of neutralized acid groups; and
wherein the mixture has a melt flow index of at least 0.5 g/10 min.
US Pat. No. 10,427,007

GOLF BALL COMPOSITIONS

Acushnet Company, Fairha...

1. A golf ball comprising an innermost core layer formed from a heterogeneous composition comprising a thermoplastic matrix and discrete particles dispersed within the matrix, wherein the discrete particles are formed from a crosslinked rubber composition having a Shore D hardness of 65 or greater, and wherein each of the discrete particles present in the composition has a particle size of from 0.030 mm to 2.38 mm, and wherein the discrete particles are present in the heterogeneous composition in an amount of 60 wt % or greater, based on the total weight of the heterogeneous composition.
US Pat. No. 10,428,288

PROCESS FOR CONVERTING A BIOMASS INTO AT LEAST ONE BIOCHAR

1. A method for transforming a biomass into at least one biochar, comprising the following steps of:(a) providing a ground and dried biomass, said biomass containing at least 30% of a lignocellulosic biomass, by mass relative to the dry weight of the ground and dried biomass and said biomass being in the form of particles with homogeneous dimensions and having a moisture content close to 0;
(b) heating progressively this biomass at a temperature higher than 140° C. and lower than 350° C., in an oxygen-free gas stream, at a pressure comprised between 1 and 40 bar until exothermic phenomenon takes off;
(c) allowing the exothermic reaction to proceed by maintaining the temperature in the 300-700° C. range and the pressure in the 1-40 bar range;
(d) cooling the biomass derived from step (c), at a temperature of at most 100° C., in an oxygen-free gas stream; and
(e) collecting the biochar,
said method being implemented without any supply of external inert gas.
US Pat. No. 10,428,290

DE-ICING LUBRICANT COMPOSITION

1. A de-icing lubricant composition, comprising:a. isopropyl alcohol comprising 60-90% of the composition by weight; and
b. mineral oil.
US Pat. No. 10,426,757

COMPOSITIONS AND METHODS FOR PROMOTING INTESTINAL STEM CELL AND/OR NON-STEM PROGENITOR CELL FUNCTION

Whitehead Institute for B...

1. A method of stimulating the proliferation and/or self-renewal of one or more intestinal stem cells in mammalian intestinal tissue in a subject, the method comprising contacting a population of cells in the mammalian intestinal tissue with an effective amount of a compound that increases the level and/or activity of peroxisome proliferator activated receptor delta (PPAR-?) or a PPAR-? target protein, thereby stimulating the proliferation and/or self-renewal of one or more intestinal stem cells, wherein the contacting of the population of cells with the effective amount of the compound occurs in a subject suffering a disease characterized by intestinal stem cells that require increased proliferation and/or self-renewal, wherein the compound comprises a PPAR-? agonist or a PPAR-? target protein agonist selected from the group consisting of a CPT1A agonist, a HMGCS2 agonist, and a FABP1 agonist.
US Pat. No. 10,428,037

METHOD FOR THE SYNTHESIS AND PURIFICATION OF ETHERS

The United States of Amer...

1. A method of purifying an ether, comprising:reacting a mixture comprising tetrahydrofurfuryl alcohol, about one-half equivalent of low work function element;
adding about one-half equivalent of a halide;
adding about one-half equivalent of low work function element and one-half equivalent of halide and reacting;
adding an excess amount of low work function element until unreacted low work function element is detected; and,
fractionally distilling said mixture to obtain the purified ether wherein said low work function element is an elemental metal or a metal hydride which has a ? of less than about 3.0 eV.
US Pat. No. 10,428,293

ENHANCED EXTREME PRESSURE LUBRICANT FORMULATIONS

Dow Global Technologies L...

1. A lubricant formulation comprising:a. at least 50 weight-percent of a hydrocarbon base oil;
b. five weight-percent or more and less than 50 weight-percent of an oil soluble polyalkylene glycol selected from a group consisting of monol, diol and triol initiated 1,2-butylene oxide homopolymers and monol initiated copolymers of 1,2-butylene oxide and propylene oxide; and
c. 0.1 weight-percent or more and five weight-percent or less of a sulfurized olefin, where weight-percent is based on total lubricant formulation weight.
US Pat. No. 10,426,759

USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

NOVARTIS AG, Basel (CH)

1. A compound which is a citrate salt of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide.
US Pat. No. 10,428,040

PROCESSES FOR THE ISOLATION OF A CANNABINOID EXTRACT AND PRODUCT FROM CANNABIS PLANT MATERIAL

1. A process for obtaining a cannabinoid extract from Cannabis plant material comprising:a) the step of providing a dispersion of material comprising cannabinoids derived from one or more Cannabis plants in an oil;
b) the step of isolating at least a portion of said cannabinoids from said dispersion to obtain a cannabinoid extract, wherein said step of isolating comprises one or both of:
A) stripping said dispersion under reduced pressure with a gaseous stripping medium to extract at least a portion of said cannabinoids from said dispersion into said gaseous stripping medium to obtain a vapour containing cannabinoids;
condensing at least part of said vapour to form a condensate; and
recovering a cannabinoid extract from said condensate; and/or
B) mixing said dispersion with a polar solvent, and forming a two-phase system with a first phase of said dispersion and a second phase of said polar solvent, wherein at least part of the cannabinoids is extracted into the second phase: isolating at least part of the second phase from the first phase; and wherein the extraction is optionally followed by
evaporating at least part of said isolated second phase to obtain a cannabinoid containing evaporation residue.
US Pat. No. 10,428,296

UNIT DOSE FABRIC SOFTENER

Colgate-Palmolive Company...

1. A unit dose fabric conditioner comprising a fabric conditioner composition contained within a water soluble pouch, wherein the composition is liquid at 25° C. and comprises:a) a cationic fabric softening active, wherein the cationic fabric softening active is at least one active chosen from esterquat, tallow esterquat, triolyeyl esterquat, and diolyeyl esterquat;
b) at least 50% by weight of the composition of a C3-C12 polyol that is liquid at 25° C.;
c) a C9-C15 alkoxylated alcohol having an average of 3 to 8 EO per mole and which is liquid at 25° C.;
d) a dispersing polymer for dispersing the cationic fabric softening active; and
encapsulated fragrance;
wherein the alkoxylated alcohol is present in an amount of 2.6 to 7.1% by weight of the composition; and
wherein the dispersing polymer is present in an amount of 1.6 to 5.8% by weight of the composition.
US Pat. No. 10,428,043

GREEN OXIDATION CATALYTIC SYSTEM

TRUSTEES OF BOSTON UNIVER...

1. A reaction mixture comprisingan oxidation catalyst comprising a metal ion complexed with an ?-keto acid and a tridentate N,N,O-ligand;
a solvent, wherein the solvent is in contact with the oxidation catalyst; and
a substrate dissolved in the solvent, wherein the solvent and the substrate are different; and wherein the solvent is a polar or polar aprotic solvent.
US Pat. No. 10,426,766

CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND

1. A method of enhancing motility of the gastrointestinal tract in a human, the method comprising administering to the human a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and the crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide, wherein a single crystal of the sulfate salt, analyzed at a temperature of ?153±1° C., is characterized by an orthorhombic unit cell with dimensions a=6.824 ?, b=16.228 ?, c=24.202 ?, ?=?=?=90°; cell volume (V) of 2680.0 ?3, and a space group of P212121(#19).
US Pat. No. 10,428,304

METHOD FOR PRODUCING B CELL POPULATION

TOKYO UNIVERSITY OF SCIEN...

1. A method for producing a B cell population, comprising culturing B cells, in which the expression of a Bach2 gene has been increased, in the presence of a means for acting on CD40 and/or a BAFF receptor.
US Pat. No. 10,428,306

METHOD AND SYSTEM FOR TISSUE TREATMENT WITH CRITICAL/SUPERCRITICAL CARBON DIOXIDE

Warsaw Orthopedic, Inc., ...

1. A method of decontaminating bone tissue, the method comprising: contacting the bone tissue having contaminants therein with carbon dioxide to decontaminate the bone tissue and form carbon dioxide having contaminants; collecting the carbon dioxide having contaminants; separating the contaminants from the collected carbon dioxide; and removing the contaminated carbon dioxide, purifying the contaminated carbon dioxide with supercritical fluid, liquefying the purified carbon dioxide and using liquid purified carbon dioxide as a cooling fluid.
US Pat. No. 10,426,772

USE OF ERGOT ALKALOIDS AS AN ANTHELMINTIC AGENT

Regents of the University...

1. A method of inhibiting or treating parasitic flatworm infection in a vertebrate, comprising:administering an effective amount of a composition comprising one or more ergot alkaloids, one or more lysergic acid amides, or any combination thereof, wherein the ergot alkaloid is an agonist or partial agonist of Schistosoma serotonergic G-protein coupled receptor.
US Pat. No. 10,428,308

MESODERM AND DEFINITIVE ENDODERM CELL POPULATIONS

Icahn School of Medicine ...

1. A method of making a cell population enriched for endoderm cells comprising culturing pluripotent stem cells in the presence of activin or nodal, and Wnt, for a time sufficient to provide brach+/HNF3?+ cells, and culturing said brach+/HNF3?+ cells in the presence of activin and an inhibitor of Wnt signalling for a time sufficient to provide a cell population enriched for endoderm cells.
US Pat. No. 10,426,774

METHODS OF TREATING CANCER HAVING AN ACTIVE WNT/?-CATENIN PATHWAY

Dana-Farber Cancer Instit...

1. A method of treating a cancer in a subject in need thereof comprising (a) determining that the subject has a Wnt/?-catenin active cancer, and (b) administering to the subject a treatment consisting of a therapeutic amount of a YES1 inhibitor, wherein the YES1 inhibitor is a nucleic acid, an antibody or an organic molecule capable of decreasing protein expression from the YES1 gene or decreasing the phosphorylation activity of YES1 protein.
US Pat. No. 10,428,310

METHODS AND COMPOSITIONS FOR GENERATING OR MAINTAINING PLURIPOTENT CELLS

Regeneron Pharmaceuticals...

1. An in vitro culture comprising:(a) a population of nave human induced pluripotent stem cells (hiPSCs) that display a morphology characterized by compact, dome-shaped colonies; and
(b) a low osmolality medium comprising a base medium and supplements, wherein the low osmolality medium comprises:
(i) a leukemia inhibitory factor (LIF) polypeptide;
(ii) a glycogen synthase kinase 3 (GSK3) inhibitor; and
(iii) a MEK inhibitor;
wherein the low osmolality medium has an osmolality of about 200 mOsm/kg to about 250 mOsm/kg.
US Pat. No. 10,428,056

HETEROCYCLIC COMPOUND

Takeda Pharmaceutical Com...

1. A method for treating Alzheimer's disease, schizophrenia, cognitive impairment associated with schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Parkinson's disease, or dementia with Lewy bodies in a mammal, comprising: administering an effective amount of 8-chloro-6-((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclopentyl)-7-methyl-2,3-dihydro-4H-1,3-benzoxazin-4-one or a salt thereof to the mammal.
US Pat. No. 10,426,777

METHODS USED TO TREAT CANCER

The Translational Genomic...

1. A pharmaceutical composition comprising:a first active ingredient, wherein the first active ingredient is propentofylline or a pharmaceutically acceptable salt thereof; and
a second active ingredient, wherein the second active ingredient is a chemotherapeutic agent selected from the group consisting of: cis-diamminedichloro platinum (II) (cisplatin), doxorubicin, 5-fluorouracil, paclitaxel, topoisomerase inhibitor, and a targeted-therapy drug.
US Pat. No. 10,428,314

HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF

The United States of Amer...

1. A vector, comprising a heterologous nucleic acid molecule encoding at least 70 contiguous residues of the amino acid sequence of SEQ ID NO: 9 (GP).
US Pat. No. 10,426,779

INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY

VIRGINIA COMMONWEALTH UNI...

1. A method of treating a solid tumor in a subject, comprising administering to the subject a hypoxia-activated bioreductive agent and one or more hypoxia-inducing agents, wherein the one or more hypoxia-inducing agents comprise combretastatin or a combretastatin derivative, wherein the hypoxia-activated bioreductive agent is tirapazamine, wherein the hypoxia-activated bioreductive agent is administered before or concurrently with the one or more hypoxia-inducing agents, and wherein the administration is in an amount effective in inducing necrosis of the solid tumor after 3 days of the administration.
US Pat. No. 10,426,782

PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR AND PROCESSES FOR THEIR PREPARATION

MILLENNIUM PHARMACEUTICAL...

1. A pharmaceutical composition comprising:(1) 10% to 50% w/w of a solid dispersion extrudate comprising:
(a) about 40% w/w of (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof, and
(b) about 60% w/w of copovidone; and
(2) 90% to 50% w/w of one or more pharmaceutically acceptable excipients,
wherein the solid dispersion extrudate comprises <3% w/w of (S)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide.
US Pat. No. 10,428,318

MUTATED SIALIDASES

1. A mutated ?2,6-transsialidase that comprises an amino acid sequence with at least 60% identity to SEQ ID No: 1, and further comprises at least one mutation selected from the group consisting of:at position 156, an amino acid selected from the group consisting of Ser, Thr, Cys, Tyr, Asn, Gln and Trp;
at position 161, an amino acid selected from the group consisting of Ala, Val, Ile, Leu, Phe, Tyr, Trp and Gly;
at position 180, an amino acid selected from the group consisting of Asp, Asn and Gln;
at position 186, an amino acid selected from the group consisting of Val, Ile, Leu, Met, Phe, Tyr, Trp, Ser, Cys and Thr;
at position 218, an amino acid selected from the group consisting of Val, Ile, Leu, Met, Phe, Tyr, Trp, Cys, Gly and Thr;
at position 222, an amino acid selected from the group consisting of Gin, Asp, Glu, Cys, Thr, Phe, Tyr, Trp, Arg, Lys and His;
at position 235, an amino acid selected from the group consisting of Arg, His, Ser, Cys, Ala, Val, Ile and Leu;
at position 242, an amino acid selected from the group consisting of Arg, His and Lys;
at position 261, an amino acid selected from the group consisting of His, Lys, Asp, Glu, Ala, Val, Leu and Phe;
at position 315, an amino acid selected from the group consisting of Ser, Thr and Cys;
at position 342, an amino acid selected from the group consisting of Ser and Cys, preferably Cys;
at position 349, an amino acid selected from the group consisting of Ser, Thr and Cys;
at position 350, an amino acid selected from the group consisting of Ser, Thr, Cys, Tyr, Trp and Phe;
at position 356, an amino acid selected from the group consisting of Ala, Val, Ile, Leu, Phe and Trp; and/or
at position 438, an amino acid selected from the group consisting of Arg, His and Lys,
wherein said mutated ?2,6-transsialidase has transsialidase and/or sialyltransferase activity with increased regioselectivity and/or increased thermostability compared to a parent ?2,6-transsialidase without the mutation.
US Pat. No. 10,428,321

ALPHA-AMYLASE VARIANTS

1. An alpha-amylase variant comprising:a) a deletion at two or more positions corresponding to positions R181, G182, D183 and G184 of the mature polypeptide of SEQ ID NO: 1,
b) a substitution at one or more positions corresponding to positions Y198, Y200, L201, Y203 and A204 of the mature polypeptide of SEQ ID NO: 1, and
c) a substitution of the methionine at the position corresponding to position M202 of the mature polypeptide of SEQ ID NO: 1,wherein the variant has at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1, and wherein the variant has alpha-amylase activity.
US Pat. No. 10,426,786

MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS

THE REGENTS OF THE UNIVER...

1. A method of preventing or terminating a seizure in a subject in need thereof, comprising administration to the subject of an effective amount of a benzodiazepine and allopregnanolone, wherein both of the benzodiazepine and the allopregnanolone are administered in a subtherapeutic dose, wherein the subject has been exposed to a nerve agent or a pesticide that can cause seizures.
US Pat. No. 10,426,788

CHEMICAL ENTITIES THAT KILL SENESCENT CELLS FOR USE IN TREATING AGE-RELATED DISEASE

Unity Biotechnology, Inc....

1. A method of killing a senescent cell, the senescent cell being characterized as a non-cancerous cell in replicative arrest, the method comprising contacting the senescent cell with an effective amount of a senolytic compound that is lethal to the senescent cell, wherein the senolytic compound is gambogic acid or a pharmaceutical salt thereof.
US Pat. No. 10,426,789

ALLELE SPECIFIC MODULATORS OF P23H RHODOPSIN

1. A compound comprising (i) a modified oligonucleotide consisting of 16 to 30 linked nucleosides having a nucleobase sequence comprising any one of SEQ ID NOs: 15, 21, or 64, or (ii) a modified oligonucleotide consisting of 15 to 30 linked nucleosides having a nucleobase sequence comprising SEQ ID NO: 29.
US Pat. No. 10,426,791

SYNERGISM OF GOS AND POLYFRUCTOSE

N.V. Nutricia, Zoetermee...

1. A method of treating eczema, the method consisting of orally administering to a mammal suffering from eczema a composition comprising galactooligosaccharide and polyfructose, wherein the weight ratio of galactooligosaccharide:polyfructose is 97:3 to 80:20, wherein the composition does not comprise lactobacilli.
US Pat. No. 10,426,801

ENCAPSULATED DIAGNOSTICS AND THERAPEUTICS IN NANOPARTICLES—CONJUGATED TO TROPIC CELLS AND METHODS FOR THEIR USE

City of Hope, Duarte, CA...

1. A therapeutic delivery vehicle comprising a gold particle coated with a cationic thiol moiety internalized by a genetically modified neural stem cell, wherein the cationic thiol moiety is 11-mercaptoundecyltrimethylammonium bromide.
US Pat. No. 10,428,338

METHODS AND COMPOSITIONS FOR INCREASING INVERTASE ACTIVITY IN PLANTS

Monsanto Technology LLC, ...

1. A composition comprising: (i) a polynucleotide molecule that comprises at least 18 contiguous nucleotides that are identical or complementary to a plant INVINH1 gene or transcript of said plant gene, wherein said polynucleotide molecule is not operably linked to a promoter or to a viral vector; and, (ii) a transfer agent comprising an organosilicone preparation that conditions a surface of a plant to permeation by the polynucleotide molecule into cells of the plant.
US Pat. No. 10,426,810

TANGERINE PEEL EXTRACT AND ITS PREPARATION AND APPLICATION

Infinitus (China) Company...

1. A method of improving glucose tolerance in an obese person comprising administering an effective amount of a tangerine (Citrus tangerine) peel extract with an acceptable carrier;wherein said tangerine peel extract is free of D-limonene and is prepared by a process comprising
(a) breaking 200 g long-term aged tangerine peel into pieces of 80 mesh;
(b) extracting the pieces of tangerine peels for one hour with supercritical carbon dioxide as an extraction medium at a flow rate of 80 L/h, under a pressure of 35 MPa and at a temperature of 50° C.
US Pat. No. 10,429,374

GENETICALLY ENCODED POTASSIUM ION INDICATORS

1. A polypeptide comprisinga) a first signaling domain, and
b) a potassium sensor comprising
1) a first domain of the potassium sensor comprising an amino acid sequence which exhibits at least 70% identity to the sequence according to SEQ ID NO: 1; and
2) a second domain of the potassium sensor comprising an amino acid sequence which exhibits at least 70% identity to the sequence according to SEQ ID NO: 2;wherein the potassium sensor is capable of binding positively charged potassium ion and the first signaling domain is capable of generating a detectable signal upon binding of positively charged potassium ion to the potassium sensor, wherein the polypeptide does not consist of SEQ ID NO:3.
US Pat. No. 10,428,093

LIPID CO-FACTOR ESSENTIAL FOR CELL DENSITY SIGNALING

1. An isolated tissue-specific lipid co-factor having a formula C63H123N2O11P and a mass of about 1114.89 MW, said lipid cofactor binds to a polypeptide factor that comprises the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 5 to form a protein/lipid cell density signaling complex, said cell density signally complex controlling cell proliferation, differentiation or apoptosis in bone and cartilage tissue, and said lipid co-factor comprising a ceramide phosphate, a glycerol lipid with a single fatty acid, and a linker.

US Pat. No. 10,432,655

IOT AND POS ANTI-MALWARE STRATEGY

Mcafee, LLC, Santa Clara...

1. A device for providing device security, the device comprising:one or more processors; and
memory including instructions which, when executed, cause the one or more processors to at least:
detect a combination of function calls;
determine whether the combination of function calls is a forbidden combination of function calls for the device based on a limited intended functionality of the device, the forbidden combination of function calls including a first function call and a second function call, the first function call allowed in isolation from the second function call, the second function call allowed in isolation from the first function call; and
in response to determining that the combination of function calls is forbidden for the device, perform a responsive action.